AVP Receptor V1a Antibody (721CT25.2.1): sc-517313

AVP Receptor V1a Antibody (721CT25.2.1) is a mouse monoclonal IgM antibody that detects AVP Receptor V1a protein of mouse, rat, and human origin by western blotting (WB) and immunoprecipitation (IP). Anti-AVP Receptor V1a antibody (721CT25.2.1) is available as a non-conjugated monoclonal isotype antibody. AVP Receptor V1a plays a crucial role in various physiological processes, including blood vessel constriction, liver glycogenolysis, and platelet adhesion, making AVP Receptor V1a essential for maintaining vascular tone and regulating blood pressure. AVP Receptor V1a is primarily located on the cell membrane and couples to Gq/11 proteins, which activate phospholipase C and lead to an increase in intracellular calcium levels. Calcium elevation is vital for numerous cellular responses, including muscle contraction and neurotransmitter release, highlighting AVP Receptor V1a′s importance in cardiovascular and renal function. AVP Receptor V1a exists in both full-length and truncated forms due to proteolytic cleavage, which may influence signaling capabilities and functional outcomes. Understanding AVP Receptor V1a dynamics and interactions with other signaling pathways can provide insights into potential therapeutic targets for conditions such as hypertension and heart failure.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

AVP Receptor V1a Antibody (721CT25.2.1) References:

1. Vasopressin receptor mutations and nephrogenic diabetes insipidus.  |  Birnbaumer, M. 1999. Arch Med Res. 30: 465-74. PMID: 10714359
2. Nephrogenic diabetes insipidus.  |  Morello, JP. and Bichet, DG. 2001. Annu Rev Physiol. 63: 607-30. PMID: 11181969
3. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists.  |  Thibonnier, M., et al. 2001. Annu Rev Pharmacol Toxicol. 41: 175-202. PMID: 11264455
4. Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus.  |  Engin, E. and Treit, D. 2008. Neuropeptides. 42: 411-21. PMID: 18508119
5. Association between arginine vasopressin 1a receptor (AVPR1a) promoter region polymorphisms and prepulse inhibition.  |  Levin, R., et al. 2009. Psychoneuroendocrinology. 34: 901-8. PMID: 19195791
6. Pleiotropic Contribution of MECOM and AVPR1A to Aggression and Subcortical Brain Volumes.  |  van Donkelaar, MMJ., et al. 2018. Front Behav Neurosci. 12: 61. PMID: 29666571
7. The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia.  |  Broniarczyk-Czarniak, M., et al. 2022. Curr Issues Mol Biol. 44: 336-349. PMID: 35723404
8. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.  |  Sugimoto, T., et al. 1994. J Biol Chem. 269: 27088-92. PMID: 7929452
9. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.  |  Thibonnier, M., et al. 1994. J Biol Chem. 269: 3304-10. PMID: 8106369
10. Evidence for expression of vasopressin V2 receptor mRNA in human lung.  |  Fay, MJ., et al. 1996. Peptides. 17: 477-81. PMID: 8735975
11. Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.  |  Phalipou, S., et al. 1997. J Biol Chem. 272: 26536-44. PMID: 9334232
12. [Hormones of the posterior region of the hypophyseal gland].  |  Mircić, GM., et al. 1998. Srp Arh Celok Lek. 126: 111-8. PMID: 9863366